LGM Pharma to expand manufacturing capabilities with $6m investment
This initiative is stated to be a part of the company’s Phase I contract development and manufacturing organisation (CDMO) growth strategy. In response to the growing need for
Health Canada has granted approval for Arcutis’ topical formulation Zoryve (roflumilast cream 0.15%) for mild to moderate atopic dermatitis (AD) treatment in adults and paediatrics aged six years and above.